Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundJAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well-recognized neurological occurrence in this context, whereas parkinsonism has received limited attention.ObjectivesTo describe parkinsonian phenotypes in patients with JAK2-mutated MPNs and explore possible pathophysiological links.MethodsWe identified five patients with a JAK2-mutated MPNs and parkinsonism and reviewed their demographic and clinical features, neuroimaging, and levodopa response.ResultsParkinsonian phenotypes were heterogeneous, including Parkinson's disease (n = 2), atypical parkinsonism (n = 1), motor neuron disease with parkinsonism (n = 1), and chorea followed by parkinsonism (n = 1). The latter patient developed parkinsonism approximately 22 months after onset of generalized chorea. When available (n = 2), DaTscan was abnormal. Levodopa responsiveness was variable.ConclusionAlthough JAK2-mutated MPNs and parkinsonism may coexist coincidentally, recent evidence suggests plausible pathophysiological links, including vascular, inflammatory, immune-mediated, and treatment-related mechanisms.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.